Do analysts rate XOMA or XOMAO?

XOMA Royalty currently has a consensus target price of $53.75, indicating a potential upside of 26.35%. Given XOMA Royalty's stronger consensus rating and higher possible upside, research analysts clearly believe XOMA Royalty is more favorable than XOMA. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XOMA Royalty 0 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.14 XOMA 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, XOMA or XOMAO?

XOMA Royalty has higher revenue and earnings than XOMA. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XOMA Royalty $52.15M 10.23 $31.71M $1.57 27.10 XOMA $7.65M N/A N/A N/A N/A

Is XOMA or XOMAO more profitable?

XOMA Royalty has a net margin of 53.46% compared to XOMA's net margin of 0.00%. XOMA Royalty's return on equity of 12.56% beat XOMA's return on equity. Company Net Margins Return on Equity Return on Assets XOMA Royalty 53.46% 12.56% 4.11% XOMA N/A N/A N/A

Does the media prefer XOMA or XOMAO?

In the previous week, XOMA Royalty had 1 more articles in the media than XOMA. MarketBeat recorded 4 mentions for XOMA Royalty and 3 mentions for XOMA. XOMA's average media sentiment score of 1.29 beat XOMA Royalty's score of 1.14 indicating that XOMA is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XOMA Royalty 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive XOMA 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, INVA or XOMA?

Innoviva has higher revenue and earnings than XOMA Royalty. Innoviva is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innoviva $411.33M 4.05 $271.17M $6.01 3.76 XOMA Royalty $52.15M 10.23 $31.71M $1.57 27.10

Is INVA or XOMA more profitable?

Innoviva has a net margin of 119.89% compared to XOMA Royalty's net margin of 53.46%. Innoviva's return on equity of 33.33% beat XOMA Royalty's return on equity. Company Net Margins Return on Equity Return on Assets Innoviva 119.89% 33.33% 22.67% XOMA Royalty 53.46% 12.56% 4.11%

Does the media favor INVA or XOMA?

In the previous week, Innoviva had 2 more articles in the media than XOMA Royalty. MarketBeat recorded 6 mentions for Innoviva and 4 mentions for XOMA Royalty. XOMA Royalty's average media sentiment score of 1.14 beat Innoviva's score of 0.38 indicating that XOMA Royalty is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral XOMA Royalty 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, NVAX or XOMA?

Novavax has higher revenue and earnings than XOMA Royalty. Novavax is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $1.12B 1.40 $440.30M -$0.58 N/A XOMA Royalty $52.15M 10.23 $31.71M $1.57 27.10

Is NVAX or XOMA more profitable?

XOMA Royalty has a net margin of 53.46% compared to Novavax's net margin of -14.73%. XOMA Royalty's return on equity of 12.56% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -14.73% -14.82% 1.23% XOMA Royalty 53.46% 12.56% 4.11%

Does the media favor NVAX or XOMA?

In the previous week, Novavax had 2 more articles in the media than XOMA Royalty. MarketBeat recorded 6 mentions for Novavax and 4 mentions for XOMA Royalty. XOMA Royalty's average media sentiment score of 1.14 beat Novavax's score of -0.25 indicating that XOMA Royalty is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral XOMA Royalty 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, XOMA or ZBIO?

XOMA Royalty has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XOMA Royalty $52.15M 10.23 $31.71M $1.57 27.10 Zenas BioPharma $10M 168.61 -$377.74M -$8.47 N/A

Does the media prefer XOMA or ZBIO?

In the previous week, XOMA Royalty and XOMA Royalty both had 4 articles in the media. XOMA Royalty's average media sentiment score of 1.14 beat Zenas BioPharma's score of 0.75 indicating that XOMA Royalty is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XOMA Royalty 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, XOMA or MNKD?

XOMA Royalty has higher earnings, but lower revenue than MannKind. MannKind is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XOMA Royalty $52.15M 10.23 $31.71M $1.57 27.10 MannKind $348.97M 3.76 $5.86M -$0.07 N/A

Is XOMA or MNKD more profitable?

XOMA Royalty has a net margin of 53.46% compared to MannKind's net margin of -6.63%. XOMA Royalty's return on equity of 12.56% beat MannKind's return on equity. Company Net Margins Return on Equity Return on Assets XOMA Royalty 53.46% 12.56% 4.11% MannKind -6.63% -11.21% -3.92%

Does the media prefer XOMA or MNKD?

In the previous week, XOMA Royalty and XOMA Royalty both had 4 articles in the media. XOMA Royalty's average media sentiment score of 1.14 beat MannKind's score of 0.37 indicating that XOMA Royalty is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XOMA Royalty 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

XOMA Royalty (XOMA) Competitors

$42.54 +0.39 (+0.93%)

As of 09:57 AM Eastern

Compare

XOMA vs. XOMAO, INVA, NVAX, ZBIO, and MNKD

Should you buy XOMA Royalty stock or one of its competitors? MarketBeat compares XOMA Royalty with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with XOMA Royalty include XOMA (XOMAO), Innoviva (INVA), Novavax (NVAX), Zenas BioPharma (ZBIO), and MannKind (MNKD). These companies are all part of the "medical" sector.

How does XOMA Royalty compare to XOMA?

XOMA Royalty (NASDAQ:XOMA) and XOMA (NASDAQ:XOMAO) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, XOMA Royalty had 1 more articles in the media than XOMA. MarketBeat recorded 4 mentions for XOMA Royalty and 3 mentions for XOMA. XOMA's average media sentiment score of 1.29 beat XOMA Royalty's score of 1.14 indicating that XOMA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XOMA Royalty	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
XOMA	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

XOMA Royalty has higher revenue and earnings than XOMA.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XOMA Royalty	$52.15M	10.23	$31.71M	$1.57	27.10
XOMA	$7.65M	N/A	N/A	N/A	N/A

XOMA Royalty currently has a consensus target price of $53.75, indicating a potential upside of 26.35%. Given XOMA Royalty's stronger consensus rating and higher possible upside, research analysts clearly believe XOMA Royalty is more favorable than XOMA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XOMA Royalty	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.14
XOMA	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

XOMA Royalty has a net margin of 53.46% compared to XOMA's net margin of 0.00%. XOMA Royalty's return on equity of 12.56% beat XOMA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XOMA Royalty	53.46%	12.56%	4.11%
XOMA	N/A	N/A	N/A

95.9% of XOMA Royalty shares are owned by institutional investors. 8.9% of XOMA Royalty shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

XOMA Royalty beats XOMA on 10 of the 11 factors compared between the two stocks.

How does XOMA Royalty compare to Innoviva?

Innoviva (NASDAQ:INVA) and XOMA Royalty (NASDAQ:XOMA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

Innoviva presently has a consensus price target of $36.20, indicating a potential upside of 60.25%. XOMA Royalty has a consensus price target of $53.75, indicating a potential upside of 26.35%. Given Innoviva's stronger consensus rating and higher probable upside, analysts plainly believe Innoviva is more favorable than XOMA Royalty.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
XOMA Royalty	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.14

Innoviva has higher revenue and earnings than XOMA Royalty. Innoviva is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	4.05	$271.17M	$6.01	3.76
XOMA Royalty	$52.15M	10.23	$31.71M	$1.57	27.10

Innoviva has a net margin of 119.89% compared to XOMA Royalty's net margin of 53.46%. Innoviva's return on equity of 33.33% beat XOMA Royalty's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
XOMA Royalty	53.46%	12.56%	4.11%

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 95.9% of XOMA Royalty shares are owned by institutional investors. 2.0% of Innoviva shares are owned by company insiders. Comparatively, 8.9% of XOMA Royalty shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Innoviva has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, XOMA Royalty has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

In the previous week, Innoviva had 2 more articles in the media than XOMA Royalty. MarketBeat recorded 6 mentions for Innoviva and 4 mentions for XOMA Royalty. XOMA Royalty's average media sentiment score of 1.14 beat Innoviva's score of 0.38 indicating that XOMA Royalty is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
XOMA Royalty	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Innoviva beats XOMA Royalty on 11 of the 16 factors compared between the two stocks.

How does XOMA Royalty compare to Novavax?

Novavax (NASDAQ:NVAX) and XOMA Royalty (NASDAQ:XOMA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

53.0% of Novavax shares are owned by institutional investors. Comparatively, 95.9% of XOMA Royalty shares are owned by institutional investors. 1.6% of Novavax shares are owned by insiders. Comparatively, 8.9% of XOMA Royalty shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Novavax has higher revenue and earnings than XOMA Royalty. Novavax is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.40	$440.30M	-$0.58	N/A
XOMA Royalty	$52.15M	10.23	$31.71M	$1.57	27.10

Novavax has a beta of 2.45, indicating that its stock price is 145% more volatile than the broader market. Comparatively, XOMA Royalty has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

XOMA Royalty has a net margin of 53.46% compared to Novavax's net margin of -14.73%. XOMA Royalty's return on equity of 12.56% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
XOMA Royalty	53.46%	12.56%	4.11%

Novavax currently has a consensus target price of $13.00, indicating a potential upside of 36.14%. XOMA Royalty has a consensus target price of $53.75, indicating a potential upside of 26.35%. Given Novavax's stronger consensus rating and higher probable upside, equities analysts clearly believe Novavax is more favorable than XOMA Royalty.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.22
XOMA Royalty	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, Novavax had 2 more articles in the media than XOMA Royalty. MarketBeat recorded 6 mentions for Novavax and 4 mentions for XOMA Royalty. XOMA Royalty's average media sentiment score of 1.14 beat Novavax's score of -0.25 indicating that XOMA Royalty is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
XOMA Royalty	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

XOMA Royalty beats Novavax on 9 of the 16 factors compared between the two stocks.

How does XOMA Royalty compare to Zenas BioPharma?

XOMA Royalty (NASDAQ:XOMA) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

95.9% of XOMA Royalty shares are owned by institutional investors. 8.9% of XOMA Royalty shares are owned by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

XOMA Royalty has a net margin of 53.46% compared to Zenas BioPharma's net margin of 0.00%. XOMA Royalty's return on equity of 12.56% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XOMA Royalty	53.46%	12.56%	4.11%
Zenas BioPharma	N/A	-99.99%	-58.06%

XOMA Royalty presently has a consensus price target of $53.75, indicating a potential upside of 26.35%. Zenas BioPharma has a consensus price target of $44.29, indicating a potential upside of 65.81%. Given Zenas BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe Zenas BioPharma is more favorable than XOMA Royalty.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XOMA Royalty	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.14
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, XOMA Royalty and XOMA Royalty both had 4 articles in the media. XOMA Royalty's average media sentiment score of 1.14 beat Zenas BioPharma's score of 0.75 indicating that XOMA Royalty is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XOMA Royalty	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

XOMA Royalty has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.71, suggesting that its share price is 171% less volatile than the broader market.

XOMA Royalty has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XOMA Royalty	$52.15M	10.23	$31.71M	$1.57	27.10
Zenas BioPharma	$10M	168.61	-$377.74M	-$8.47	N/A

Summary

XOMA Royalty beats Zenas BioPharma on 10 of the 15 factors compared between the two stocks.

How does XOMA Royalty compare to MannKind?

XOMA Royalty (NASDAQ:XOMA) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

XOMA Royalty has higher earnings, but lower revenue than MannKind. MannKind is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XOMA Royalty	$52.15M	10.23	$31.71M	$1.57	27.10
MannKind	$348.97M	3.76	$5.86M	-$0.07	N/A

95.9% of XOMA Royalty shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 8.9% of XOMA Royalty shares are held by insiders. Comparatively, 2.6% of MannKind shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

XOMA Royalty has a net margin of 53.46% compared to MannKind's net margin of -6.63%. XOMA Royalty's return on equity of 12.56% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XOMA Royalty	53.46%	12.56%	4.11%
MannKind	-6.63%	-11.21%	-3.92%

XOMA Royalty has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, MannKind has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

In the previous week, XOMA Royalty and XOMA Royalty both had 4 articles in the media. XOMA Royalty's average media sentiment score of 1.14 beat MannKind's score of 0.37 indicating that XOMA Royalty is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XOMA Royalty	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

XOMA Royalty presently has a consensus price target of $53.75, indicating a potential upside of 26.35%. MannKind has a consensus price target of $8.97, indicating a potential upside of 111.28%. Given MannKind's stronger consensus rating and higher probable upside, analysts plainly believe MannKind is more favorable than XOMA Royalty.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XOMA Royalty	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.14
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

XOMA Royalty beats MannKind on 10 of the 15 factors compared between the two stocks.

Get XOMA Royalty News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XOMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XOMA vs. The Competition

Export

Metric	XOMA Royalty	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$533.45M	$3.66B	$7.07B	$12.45B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	27.10	20.90	27.24	24.87
Price / Sales	10.23	341.80	542.17	102.84
Price / Cash	73.93	143.77	48.53	58.59
Price / Book	6.28	8.75	10.95	6.54
Net Income	$31.71M	$23.81M	$3.57B	$336.70M
7 Day Performance	0.93%	3.60%	2.27%	2.81%
1 Month Performance	2.04%	3.72%	1.35%	0.59%
1 Year Performance	61.50%	68.80%	36.71%	31.29%

XOMA Royalty Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XOMA XOMA Royalty	3.1517 of 5 stars	$42.54 +0.9%	$53.75 +26.4%	+68.7%	$533.45M	$52.15M	27.10	10	Positive News
XOMAO XOMA	N/A	$25.43 0.0%	N/A	+0.2%	$0.00	$7.65M	N/A	10	News Coverage Short Interest Decrease
INVA Innoviva	3.5547 of 5 stars	$23.29 +2.7%	$36.20 +55.4%	+13.0%	$1.72B	$411.33M	3.87	100
NVAX Novavax	1.717 of 5 stars	$9.26 +2.9%	$13.00 +40.3%	+49.5%	$1.52B	$1.12B	N/A	1,990
ZBIO Zenas BioPharma	3.3801 of 5 stars	$20.66 -0.7%	$44.29 +114.4%	+161.9%	$1.30B	N/A	N/A	N/A	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XOMA) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

XOMA Royalty (XOMA) Competitors

XOMA vs. XOMAO, INVA, NVAX, ZBIO, and MNKD

How does XOMA Royalty compare to XOMA?

Summary

How does XOMA Royalty compare to Innoviva?

Summary

How does XOMA Royalty compare to Novavax?

Summary

How does XOMA Royalty compare to Zenas BioPharma?

Summary

How does XOMA Royalty compare to MannKind?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XOMA vs. The Competition

XOMA Royalty Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

XOMA Royalty (XOMA) Competitors

XOMA vs. XOMAO, INVA, NVAX, ZBIO, and MNKD

How does XOMA Royalty compare to XOMA?

Does the media prefer XOMA or XOMAO?

Which has preferable earnings & valuation, XOMA or XOMAO?

Do analysts rate XOMA or XOMAO?

Is XOMA or XOMAO more profitable?

Do insiders and institutionals believe in XOMA or XOMAO?

Summary

How does XOMA Royalty compare to Innoviva?

Do analysts rate INVA or XOMA?

Which has stronger valuation & earnings, INVA or XOMA?

Is INVA or XOMA more profitable?

Do institutionals & insiders believe in INVA or XOMA?

Which has more risk and volatility, INVA or XOMA?

Does the media favor INVA or XOMA?

Summary

How does XOMA Royalty compare to Novavax?

Do institutionals and insiders believe in NVAX or XOMA?

Which has better earnings and valuation, NVAX or XOMA?

Which has more volatility and risk, NVAX or XOMA?

Is NVAX or XOMA more profitable?

Do analysts rate NVAX or XOMA?

Does the media favor NVAX or XOMA?

Summary

How does XOMA Royalty compare to Zenas BioPharma?

Do institutionals & insiders have more ownership in XOMA or ZBIO?

Is XOMA or ZBIO more profitable?

Do analysts rate XOMA or ZBIO?

Does the media prefer XOMA or ZBIO?

Which has more volatility and risk, XOMA or ZBIO?

Which has higher valuation & earnings, XOMA or ZBIO?

Summary

How does XOMA Royalty compare to MannKind?

Which has higher earnings and valuation, XOMA or MNKD?

Do insiders & institutionals have more ownership in XOMA or MNKD?

Is XOMA or MNKD more profitable?

Which has more risk and volatility, XOMA or MNKD?

Does the media prefer XOMA or MNKD?

Do analysts recommend XOMA or MNKD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XOMA vs. The Competition

XOMA Royalty Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools